MX9304837A - Peptidos capaces de inhibir la actividad de proteasa vih, su preparacion y su uso terapeutico. - Google Patents
Peptidos capaces de inhibir la actividad de proteasa vih, su preparacion y su uso terapeutico.Info
- Publication number
- MX9304837A MX9304837A MX9304837A MX9304837A MX9304837A MX 9304837 A MX9304837 A MX 9304837A MX 9304837 A MX9304837 A MX 9304837A MX 9304837 A MX9304837 A MX 9304837A MX 9304837 A MX9304837 A MX 9304837A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibit
- peptides
- activity
- preparation
- hiv protease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a una serie de nuevos péptidos que tienen la habilidad de inhibir la actividad de proteasa que se origina en el virus de inmunodeficiencia humano (VIH), de aquí en adelante denominado como 'proteasa de VIH'. Los compuestos de esta manera tienen la capacidad de interferir con la maduración y replicación del virus y de esta forma pueden ser utilizados para tratar individuos infectados por el VIH. Esta invención provee también métodos y composiciones que utilizan estos compuestos así como procedimientos para prepararlos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21174692 | 1992-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9304837A true MX9304837A (es) | 1994-05-31 |
Family
ID=16610902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9304837A MX9304837A (es) | 1992-08-07 | 1993-08-09 | Peptidos capaces de inhibir la actividad de proteasa vih, su preparacion y su uso terapeutico. |
Country Status (16)
Country | Link |
---|---|
US (1) | US5629406A (es) |
EP (1) | EP0587311A1 (es) |
KR (1) | KR0177838B1 (es) |
CN (1) | CN1091432A (es) |
AU (1) | AU662434B2 (es) |
CA (1) | CA2103536A1 (es) |
CZ (1) | CZ161993A3 (es) |
FI (1) | FI933472A (es) |
HU (1) | HUT64774A (es) |
IL (1) | IL106600A (es) |
MX (1) | MX9304837A (es) |
NO (1) | NO932813L (es) |
NZ (1) | NZ248332A (es) |
PH (1) | PH31249A (es) |
RU (1) | RU2106357C1 (es) |
ZA (1) | ZA935697B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6313094B1 (en) | 1990-12-11 | 2001-11-06 | Japan Energy Corporation | β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors |
DE69524527D1 (de) * | 1994-10-14 | 2002-01-24 | Japan Energy Corp | AIDS-hemmende Arzneizubereitung und Verfahren |
DE19512484A1 (de) | 1995-04-04 | 1996-10-17 | Bayer Ag | Kohlenhydratmodifizierte Cytostatika |
US6008228A (en) * | 1995-06-06 | 1999-12-28 | Hoffman-La Roche Inc. | Pharmaceutical compositions containing proteinase inhibitors |
CA2179935C (en) * | 1995-06-30 | 2010-09-07 | Ryohei Kato | Novel dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof |
US6222043B1 (en) | 1995-06-30 | 2001-04-24 | Japan Energy Corporation | Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof |
CA2249747A1 (en) | 1996-12-27 | 1998-07-09 | Tsutomu Mimoto | Novel tripeptide compounds and anti-aids drugs |
JP4006058B2 (ja) | 1997-03-11 | 2007-11-14 | 第一三共株式会社 | 多臓器不全予防及び/又は治療剤 |
CA2253629A1 (en) | 1997-03-14 | 1998-09-24 | Snow Brand Milk Products Co., Ltd. | Agent for preventing and/or treating cachexia |
KR20000022426A (ko) * | 1997-05-14 | 2000-04-25 | 토미모토 요시히사 | Hiv-1프로테아제 저해제, 그 제조방법 및 의약조성물 |
ES2147162B1 (es) | 1999-01-27 | 2001-03-16 | Lacer Sa | "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias". |
SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
CO5300399A1 (es) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
US7005439B2 (en) | 2000-06-20 | 2006-02-28 | Astrazeneca Ab | Compounds |
GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
AR035230A1 (es) | 2001-03-19 | 2004-05-05 | Astrazeneca Ab | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
WO2002081454A1 (en) * | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
CN1307875C (zh) | 2001-04-27 | 2007-04-04 | 宝洁公司 | 用于控制生物膜的化合物、组合物和方法 |
US7169932B2 (en) * | 2001-06-11 | 2007-01-30 | Pfizer Inc. | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis |
HN2002000136A (es) * | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
US7094909B2 (en) * | 2001-06-11 | 2006-08-22 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
US7067517B2 (en) | 2001-12-14 | 2006-06-27 | Nero Nordisk A/S | Use of compounds for decreasing activity of hormone-sensitive lipase |
SE0301369D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
AU2004295186A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Inc. | Methods of preparing compounds useful as protease inhibitors |
EP1692119A1 (en) * | 2003-12-04 | 2006-08-23 | Pfizer Inc. | Methods of preparing compounds useful as protease inhibitors |
WO2005121094A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Limited | Piperazine and piperidine derivatives as anti-hiv-agents |
TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
FR2904317A1 (fr) | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
EP2085390A1 (en) | 2008-01-31 | 2009-08-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2056911C (en) * | 1990-12-11 | 1998-09-22 | Yuuichi Nagano | Hiv protease inhibitors |
CA2060844A1 (en) * | 1991-02-08 | 1992-08-09 | Yabe Yuichiro | Beta-amino-alpha-hydroxycarboxylic acids and their use |
-
1993
- 1993-08-05 ZA ZA935697A patent/ZA935697B/xx unknown
- 1993-08-05 FI FI933472A patent/FI933472A/fi unknown
- 1993-08-05 IL IL106600A patent/IL106600A/xx not_active IP Right Cessation
- 1993-08-05 AU AU44438/93A patent/AU662434B2/en not_active Ceased
- 1993-08-05 NZ NZ248332A patent/NZ248332A/xx unknown
- 1993-08-06 NO NO932813A patent/NO932813L/no unknown
- 1993-08-06 CZ CZ931619A patent/CZ161993A3/cs unknown
- 1993-08-06 CA CA002103536A patent/CA2103536A1/en not_active Abandoned
- 1993-08-06 RU RU93050122A patent/RU2106357C1/ru active
- 1993-08-06 PH PH46649A patent/PH31249A/en unknown
- 1993-08-06 HU HU9302286A patent/HUT64774A/hu unknown
- 1993-08-06 EP EP93306258A patent/EP0587311A1/en not_active Withdrawn
- 1993-08-06 KR KR1019930015304A patent/KR0177838B1/ko not_active IP Right Cessation
- 1993-08-07 CN CN93117625A patent/CN1091432A/zh active Pending
- 1993-08-09 MX MX9304837A patent/MX9304837A/es unknown
-
1994
- 1994-04-14 US US08/227,588 patent/US5629406A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
PH31249A (en) | 1998-06-18 |
RU2106357C1 (ru) | 1998-03-10 |
FI933472A (fi) | 1994-02-08 |
FI933472A0 (fi) | 1993-08-05 |
CZ161993A3 (en) | 1994-02-16 |
KR940003965A (ko) | 1994-03-14 |
CN1091432A (zh) | 1994-08-31 |
NZ248332A (en) | 1995-01-27 |
US5629406A (en) | 1997-05-13 |
EP0587311A1 (en) | 1994-03-16 |
AU4443893A (en) | 1994-02-10 |
IL106600A0 (en) | 1993-12-08 |
AU662434B2 (en) | 1995-08-31 |
NO932813D0 (no) | 1993-08-06 |
HUT64774A (en) | 1994-02-28 |
HU9302286D0 (en) | 1993-10-28 |
CA2103536A1 (en) | 1994-02-08 |
IL106600A (en) | 1997-09-30 |
KR0177838B1 (ko) | 1999-04-01 |
ZA935697B (en) | 1994-03-10 |
NO932813L (no) | 1994-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9304837A (es) | Peptidos capaces de inhibir la actividad de proteasa vih, su preparacion y su uso terapeutico. | |
AR024227A1 (es) | Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas | |
ES2018478B3 (es) | Un sistema para preparar una composicion desensibilizante dental. | |
LTC1131065I2 (lt) | Dialkilfumaratai, skirti autoimuninėms ligoms gydyti | |
MX9403380A (es) | Inhibidores de proteasa de vih utiles para el tratamiento de sida. | |
MX9204454A (es) | Derivados de tiourea para inhibir la replicacion del virus de inmunodeficiencia humana y formulado farmaceutico que los contiene. | |
ES2161085T3 (es) | Formulaciones que contienen oxaliplatino. | |
AR023806A1 (es) | Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas | |
AR012671A1 (es) | Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos | |
AR004700A1 (es) | 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento | |
MX9300407A (es) | Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion. | |
ES2036553T3 (es) | Composiciones farmaceuticas que tienen actividad antineoplastica. | |
MX173567B (es) | Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih | |
MX9308005A (es) | Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene. | |
PE20010747A1 (es) | Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina | |
ES2174921T3 (es) | Inhibidores de la proteasa del vih. | |
BR9711647A (pt) | Novos derivados de ácido dicafeoilquìmico, seu uso, composições com os mesmos e métodos de tratamento usando-os. | |
ES2185655T3 (es) | Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso. | |
MX9300399A (es) | Derivados heterotriciclicos. | |
MX9303572A (es) | Inhibidores de proteasa del sindrome de inmunodeficiencia humana, procedimiento para su preparacion y formualcion farmaceutica que los contiene. | |
MX9308025A (es) | Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene. | |
ES2103577T3 (es) | Compuestos antiviricos de naftoquinona, composiciones que los contienen y utilizaciones de estos compuestos. | |
ES2089286T3 (es) | Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos. | |
ES2145114T3 (es) | Combinacion de atovacuona con proguanil para el tratamiento de infecciones protozoarias. | |
MX9401172A (es) | Derivados fluorados de 4-aminoandrostadienona, procesamiento para su preparacion y composiciones farmaceuticas que los contienen. |